Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors

Circulation

Volumn 133, Issue 13, 2016, Pages 1230-1239

  Leander, Karin ^a   Mälarstig, Anders ^a,b,d   Van'T Hooft, Ferdinand M ^b   Hyde, Craig ^d   Hellénius, Mai Lis ^c   Troutt, Jason S ^e   Konrad, Robert J ^e   Öhrvik, John ^b   Hamsten, Anders ^b   De Faire, Ulf ^a,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Cardiovascular Genetics and Genomics Group   (United States)

^c Department of Medicine ^*  (United States)

^d PFIZER INC   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

biomarkers; cardiovascular diseases; enzymes; epidemiology; follow up studies

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE REGISTRY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL INACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; UNSTABLE ANGINA PECTORIS; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; MIDDLE AGED; PREDICTIVE VALUE; PROSPECTIVE STUDY; REGISTER; RISK FACTOR; SWEDEN;

BIOMARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPROTEIN CONVERTASES; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SERINE ENDOPEPTIDASES; SWEDEN;

EID: 84959083162     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.018531     Document Type: Article

References (30)

1. Dadu RT, Ballantyne CM, Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014 11 563 575. doi: 10.1038/nrcardio.2014.84.
2. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1489 1499. doi: 10.1056/NEJMoa1501031.
3. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation Against LDL Cholesterol (OSLER) Investigators Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1500 1509. doi: 10.1056/NEJMoa1500858.
4. Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM, Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 2015 132 1648 1666. doi: 10.1161/CIRCULATIONAHA.115.016080.
5. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 34 154 156. doi: 10.1038/ng1161.
6. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006 354 1264 1272. doi: 10.1056/NEJMoa054013.
7. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006 116 2995 3005. doi: 10.1172/JCI29383.
8. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007 282 18602 18612. doi: 10.1074/jbc.M702027200.
9. Qian YW, Schmidt RJ, Zhang Y, Chu S, Lin A, Wang H, Wang X, Beyer TP, Bensch WR, Li W, Ehsani ME, Lu D, Konrad RJ, Eacho PI, Moller DE, Karathanasis SK, Cao G, Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007 48 1488 1498. doi: 10.1194/jlr.M700071-JLR200.
10. Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers JW, Boileau C, Seidah NG, Prat A, In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem 2011 286 4257 4263. doi: 10.1074/jbc.M110.192104.
11. Du F, Hui Y, Zhang M, Linton MF, Fazio S, Fan D, Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem 2011 286 43054 43061. doi: 10.1074/jbc.M111.273474.
12. Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M, Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9. J Clin Endocrinol Metab 2015 100 E41 E49. doi: 10.1210/jc.2014-3066.
13. Chernogubova E, Strawbridge R, Mahdessian H, Mälarstig A, Krapivner S, Gigante B, Hellénius ML, de Faire U, Franco-Cereceda A, Syvänen AC, Troutt JS, Konrad RJ, Eriksson P, Hamsten A, van 't Hooft FM, Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels. Arterioscler Thromb Vasc Biol 2012 32 1526 1534. doi: 10.1161/ATVBAHA.111.240549.
14. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH, Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009 94 2537 2543. doi: 10.1210/jc.2009-0141.
15. Persson L, Cao G, Ståhle L, Sjöberg BG, Troutt JS, Konrad RJ, Gälman C, Wallén H, Eriksson M, Hafström I, Lind S, Dahlin M, Amark P, Angelin B, Rudling M, Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 2010 30 2666 2672. doi: 10.1161/ATVBAHA.110.214130.
16. Halldin M, Rosell M, de Faire U, Hellénius ML, The metabolic syndrome: prevalence and association to leisure-time and work-related physical activity in 60-year-old men and women. Nutr Metab Cardiovasc Dis 2007 17 349 357. doi: 10.1016/j.numecd.2006.01.002.
17. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO, External review and validation of the Swedish national inpatient register. BMC Public Health 2011 11 450. doi: 10.1186/1471-2458-11-450.
18. Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ, Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007 53 1814 1819. doi: 10.1373/clinchem.2007.091280.
19. Heinzl H, Kaider A, Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997 54 201 208
20. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB, General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008 117 743 753. doi: 10.1161/CIRCULATIONAHA.107.699579.
21. Pencina MJ, D'Agostino RB, Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004 23 2109 2123. doi: 10.1002/sim.1802.
22. Cook NR, Ridker PM, Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009 150 795 802
23. Leening MJ, Steyerberg EW, Van Calster B, D'Agostino RB Sr, Pencina MJ, Net reclassification improvement and integrated discrimination improvement require calibrated models: relevance from a marker and model perspective. Stat Med 2014 33 3415 3418. doi: 10.1002/sim.6133.
24. Akram ON, Bernier A, Petrides F, Wong G, Lambert G, Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol 2010 30 1279 1281. doi: 10.1161/ATVBAHA.110.209007.
25. Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada TA, Fjell CD, Thair SA, Cirstea MS, Boyd JH, PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med 2014 6 258ra143. doi: 10.1126/scitranslmed.3008782.
26. Zhu YM, Anderson TJ, Sikdar K, Fung M, McQueen MJ, Lonn EM, Verma S, Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention. Arterioscler Thromb Vasc Biol 2015 35 2254 2259. doi: 10.1161/ATVBAHA.115.306172.
27. Brouwers MC, van Greevenbroek MM, Konrad RJ, Troutt JS, Schaper NC, Stehouwer CD, Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ϵ2. Clin Sci (Lond) 2014 126 679 684. doi: 10.1042/CS20130556.
28. Ridker PM, Rifai N, Bradwin G, Rose L, Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. Eur Heart J 2016 37 554 560. doi: 10.1093/eurheartj/ehv568.
29. Humphries SE, Neely RD, Whittall RA, Troutt JS, Konrad RJ, Scartezini M, Li KW, Cooper JA, Acharya J, Neil A, Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9. Clin Chem 2009 55 2153 2161. doi: 10.1373/clinchem.2009.129759.
30. Siontis GC, Tzoulaki I, Siontis KC, Ioannidis JP, Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ 2012 344 e3318